Literature DB >> 42151

Catecholamine-mediated arrhythmias in acute myocardial infarction. Experimental evidence and role of beta-adrenoceptor blockade.

L H Opie, W F Lubbe.   

Abstract

Ventricular fibrillation is a major mechanism of sudden death. The cellular link between catecholamine activity and the development of serious ventricular arrhythmias may be in the formation of cyclic adenosine monophosphate (cAMP). Cyclic AMP and agents promoting cAMP accumulation allow development of slow responses which, especially in the presence of regional ischaemia, could develop into ventricular fibrillation. The role of beta-antagonist agents in the therapy of acute myocardial infarction is analysed in relation to the hypothesis linking cAMP and ventricular fibrillation. Reasons for the limited effectiveness of anti-arrhythmic therapy with beta-antagonist agents are given.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 42151

Source DB:  PubMed          Journal:  S Afr Med J


  5 in total

1.  Changes in the incidence and duration of ventricular fibrillation in dependence on the extraneuronal accumulation of isoprenaline in the perfused rat heart.

Authors:  K Sono; K Kurahashi; M Fujiwara
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

2.  Development of a severe model of early coronary artery ligation-induced dysrhythmias in the anaesthetized rat.

Authors:  R J Marshall; A W Muir; E Winslow
Journal:  Br J Pharmacol       Date:  1981-08       Impact factor: 8.739

3.  Antiarrhythmic effects of DPI 201-106.

Authors:  G Scholtysik; F M Williams
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

4.  Carbachol and dibutyryl cyclic GMP on the vulnerability to ventricular fibrillation in rat isolated hearts.

Authors:  A Daugherty; B Woodward
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

5.  DPI 201-106, a novel cardioactive agent. Combination of cAMP-independent positive inotropic, negative chronotropic, action potential prolonging and coronary dilatory properties.

Authors:  G Scholtysik; R Salzmann; R Berthold; J W Herzig; U Quast; R Markstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.